Evogliptin

Evogliptin
Clinical data
Trade names	Suganon
Other names	DA-1229
Routes of; administration	By mouth
ATC code	A10BH07 (WHO) ;
Identifiers
	IUPAC name (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-{[(2-methyl-2-propanyl)oxy]methyl}-2-piperazinone;
CAS Number	1222102-29-5;
PubChem CID	25022354;
ChemSpider	26339341;
UNII	09118300L7;
KEGG	D11023;
ChEMBL	ChEMBL1779710;
CompTox Dashboard (EPA)	DTXSID00153545 ;
Chemical and physical data
Formula	C19H26F3N3O3
Molar mass	401.430 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N;
	InChI InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1; Key:LCDDAGSJHKEABN-MLGOLLRUSA-N;

Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.^[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea^[2] and Russia.^[3] In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. ^[4]

References

^ McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763. S2CID 46450821.
^ "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. Archived from the original on June 30, 2022. Retrieved February 1, 2017.
^ "Evodine (evogliptin) film-coated tablets. Full prescribing information". Russian State Register of Medicines (in Russian).
^ Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020). "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis". Indian J Endocrinol Metab. 24 (5): 434–445. doi:10.4103/ijem.IJEM_418_20. PMC 7810058. PMID 33489850.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[pmid19577404-1] McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763. S2CID 46450821.

[2] "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. Archived from the original on June 30, 2022. Retrieved February 1, 2017.

[3] "Evodine (evogliptin) film-coated tablets. Full prescribing information". Russian State Register of Medicines (in Russian).

[4] Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020). "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis". Indian J Endocrinol Metab. 24 (5): 434–445. doi:10.4103/ijem.IJEM_418_20. PMC 7810058. PMID 33489850.

[1]

[2]

[3]

[4]